To evaluate TARC in patients with fever, lymphadenopathy or non-Hodgkin lymphoma
ID
Source
Brief title
Condition
- Other condition
- Lymphomas Hodgkin's disease
- Ancillary infectious topics
Synonym
Health condition
andere ziekten gepaard met lymfeklier vergroting
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Mean TARC levels (pg/mL) in correlation with final diagnosis.
Secondary outcome
Not applicable.
Background summary
Thymus and activation regulated chemokine (TARC) is elevated in about 90% of
patients with classical Hodgkin lymphoma (cHL). TARC levels correspond with
tumour volume and are used as a biomarker for treatment response. It is unclear
whether TARC levels are also influenced by inflammatory states or can be
elevated in patients with lymphadenopathy or other subtypes of lymphoma.
Study objective
To evaluate TARC in patients with fever, lymphadenopathy or non-Hodgkin
lymphoma
Study design
This is a prospective study to determine TARC levels in patients with lymph
node enlargement of unknown origin, fever and in patients who are already
diagnosed with non-Hodgkin lymphoma subtypes. TARC levels will be matched with
final diagnosis and compared with TARC levels of healthy controls and patients
with Hodgkin lymphoma, which have already been collected in previous studies.
Study burden and risks
Since this study only involves a single blood draw during routine diagnostic
procedures there is no additional safety risk.
Hanzeplein 1
Groningen 9700 RB
NL
Hanzeplein 1
Groningen 9700 RB
NL
Listed location countries
Age
Inclusion criteria
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- Age * 18 years;
- Ability to give written informed consent;
And one of the following:
(1) Lymph node enlargement of unknown cause for whicha diagnostic fine needle aspiration will be performedor
(2) Presenting with fever at the emergency department or
(3) Presenting with newly diagnosed or relapsed nodular lymphocyte predominant or non-Hodgkin lymphoma.
Exclusion criteria
A potential subject who meets any of the following criteria will be excluded from participation in this study (applicable to all subgroups):
- Ineligibility to give written informed consent;
- Patients with active atopic disease or hepatic failure;
- Patients already diagnosed with Hodgkin lymphoma
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL59373.042.16 |
| Other | nummer volgt |